Pathology: Extensive stage SCLC (Es-SCLC) - maintenance (M); Extensive stage SCLC (Es-SCLC) - 1st Line (L1);
Extensive stage SCLC (Es-SCLC) - maintenance (M) | Extensive stage SCLC (Es-SCLC) - 1st Line (L1) | ||
CheckMate 451 (NI ; all population), 2019 | CASPIAN (DT ; all population), 2019 | ||
nivolumab plus ipilimumab | 1 | T1 | |
durvalumab plus tremelimumab plus SoC | 1 | T1 | |
placebo | 0 | T0 | |
etoposide plus platin | 0 | T0 |